NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
10 trialsNCT02279719 2023-11-15
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT01271504 2021-05-12
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1/2 Completed
NCT02560779 2020-07-17
Trial of TRC105 and Sorafenib in Patients With HCC
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT00785226 2016-10-17
RDEA119 and Sorafenib Combination Dose Escalation Study
Bayer
Phase 1/2 Completed
NCT00862082 2013-08-23
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Proacta, Incorporated
Phase 1/2 Terminated
NCT00882869 2011-07-13
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Aegera Therapeutics
Phase 1/2 Completed
NCT00791544 2010-08-04
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Sanofi
Phase 1/2 Terminated
NCT00389285 2009-05-27
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
ZymoGenetics
Phase 1/2 Completed